Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Sees Large Increase in Short Interest

Posted by George Bondi on Nov 2nd, 2026

Enlivex Therapeutics Ltd. (NASDAQ:ENLV – Get Free Report) was the recipient of a large growth in short interest in the month of October. As of October 15th, there was short interest totaling 159,295 shares, a growth of 61.6% from the September 30th total of 98,600 shares. Currently, 1.0% of the shares of the company are sold short. Based on an average daily volume of 3,958,965 shares, the days-to-cover ratio is currently 0.0 days.

Hedge Funds Weigh In On Enlivex Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ENLV. WINTON GROUP Ltd purchased a new position in shares of Enlivex Therapeutics in the second quarter worth about $55,000. Susquehanna International Group LLP lifted its stake in shares of Enlivex Therapeutics by 1,428.5% during the 2nd quarter. Susquehanna International Group LLP now owns 157,648 shares of the company’s stock valued at $87,000 after buying an additional 147,334 shares in the last quarter. Finally, Bank of America Corp DE lifted its stake in shares of Enlivex Therapeutics by 53.2% during the 1st quarter. Bank of America Corp DE now owns 130,401 shares of the company’s stock valued at $121,000 after buying an additional 45,303 shares in the last quarter. Institutional investors own 1.02% of the company’s stock.

Enlivex Therapeutics Trading Down 17.9%

Shares of ENLV stock traded down $0.32 on Monday, hitting $1.46. 72,260 shares of the stock were exchanged, compared to its average volume of 23,992. The firm has a market capitalization of $2.24 million, a PE ratio of -0.01 and a beta of 1.63. Enlivex Therapeutics has a one year low of $1.48 and a one year high of $434.40. The firm’s 50 day moving average is $10.56 and its two-hundred day moving average is $139.53.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the company. Wall Street Zen upgraded Enlivex Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 29th. Zacks Research lowered shares of Enlivex Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, October 2nd. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Enlivex Therapeutics in a report on Tuesday, September 22nd. One research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Enlivex Therapeutics has a consensus rating of “Hold” and an average price target of $4,800.00.

Get Our Latest Report on ENLV

Enlivex Therapeutics Company Profile

(Get Free Report)

Enlivex Therapeutics Ltd. (NASDAQ: ENLV) is an Israel-based clinical-stage biotechnology company developing cell-based immunotherapies designed to restore balance to dysregulated immune responses. The company’s approach is intended to address conditions in which excessive or uncontrolled inflammation contributes to disease progression.

Enlivex’s lead product candidate is Allocetra-OTS, an off-the-shelf cell therapy made from apoptotic cells. The therapy is designed to reprogram the immune system toward a balanced state by helping regulate the activity of immune cells, including macrophages.